BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients

Friedlaender, Alex; Vuilleumier, Aurélie; Viassolo, Valeria; Ayme, Aurélie; De Talhouet, Solène; Combes, Jean-Damien; Peron, Julien; Bodmer, Alexandre; Giraud, Sophie; Buisson, Adrien; Bonadona, Valerie; Bouchardy, Isabelle; Tredan, Olivier; Chappuis, Pierre; Labidi-Galy, Sana Intidhar

doi:10.1007/s10549-018-05127-2

Scientific article

English

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients

ContributorsFriedlaender, Alex; Vuilleumier, Aurélie; Viassolo, Valeria; Ayme, Aurélie; De Talhouet, Solène; Combes, Jean-Damien; Peron, Julien; Bodmer, Alexandre; Giraud, Sophie; Buisson, Adrien; Bonadona, Valerie; Bouchardy, Isabelle; Tredan, Olivier; Chappuis, Pierre; Labidi-Galy, Sana Intidhar

Published inBreast Cancer Research and Treatment, vol. 174, no. 3, p. 775-783

Publication date2019

Abstract

BRCA1 and BRCA2 proteins are central to DNA repair process through homologous recombination. We hypothesize that BRCA1/BRCA2 mutation carriers may exhibit increased hematological toxicity when receiving genotoxic chemotherapy.

Affiliation entities

Citation (ISO format)

FRIEDLAENDER, Alex et al. BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients. In: Breast Cancer Research and Treatment, 2019, vol. 174, n° 3, p. 775–783. doi: 10.1007/s10549-018-05127-2

Article (Published version)

Identifiers

PID : unige:120074
DOI : 10.1007/s10549-018-05127-2
PMID : 30635808

Journal ISSN0167-6806

443views

3downloads

Creation04/04/2019 14:25:00

First validation04/04/2019 14:25:00

Update15/03/2023 17:42:39

Status update15/03/2023 17:42:38

Last indexation31/10/2024 13:41:13

Archive ouverte UNIGE

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients

BRCA1 and BRCA2 proteins are central to DNA repair process through homologous recombination. We hypothesize that BRCA1/BRCA2 mutation carriers may exhibit increased hematological toxicity when receiving genotoxic chemotherapy.

Technical informations